Turkish Version of the Neurogenic Bladder Symptom Score Short Form

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGaziantep Islam Science and Technology University

About this trial

This observational study aims to evaluate the cross-cultural adaptation and psychometric properties of the Turkish version of the Neurogenic Bladder Symptom Score Short Form (NBSS-SF) in adults with spinal cord injury or multiple sclerosis who have neurogenic lower urinary tract dysfunction. Neurogenic bladder symptoms, such as urinary incontinence, urgency, and difficulties with urine storage or emptying, may negatively affect daily functioning and quality of life. In this study, the validity and reliability of the Turkish NBSS-SF will be examined, and convergent validity will be assessed through its relationship with the King's Health Questionnaire (KHQ) and the Short Form-12 (SF-12). In eligible participants, the scale will be administered again after 7 to 14 days. The aim of the study is to provide a valid and reliable Turkish patient-reported outcome measure for use in clinical practice and research.

Eligibility criteria

Qualifiers

Being ≥18 years old

Having a diagnosis of Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) and neurogenic lower urinary tract dysfunction

Being able to read and understand Turkish and have the cognitive ability to independently complete questionnaires

Can be included with any bladder management method (spontaneous voiding, CIC, permanent catheter, condom catheter, reconstruction/diversion etc.)

Disqualifiers

Having an active urinary tract infection (UTI)

Having undergone urological surgery in the last month

Reporting changes in bladder/urinary function between the first and second applications (surgery, UTI, change in bladder medication)

Having a significant recent change in general health status

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators